Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.400
-0.020 (-1.41%)
At close: Nov 20, 2024, 4:00 PM
1.450
+0.050 (3.57%)
After-hours: Nov 20, 2024, 5:34 PM EST
Regulus Therapeutics Employees
Regulus Therapeutics had 30 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
30
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,387,600
Market Cap
91.70M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
23andMe Holding Co. | 582 |
FONAR | 520 |
PetMed Express | 287 |
Veru Inc. | 189 |
Generation Bio Co. | 174 |
Immunic | 77 |
Assertio Holdings | 53 |
MediciNova | 13 |
RGLS News
- 13 days ago - Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - PRNewsWire
- 6 weeks ago - Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 3 months ago - Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - PRNewsWire
- 3 months ago - Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - PRNewsWire
- 3 months ago - Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PRNewsWire
- 5 months ago - Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 6 months ago - Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes - PRNewsWire
- 6 months ago - Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - PRNewsWire